Evidence mapPaperPMID 34511231Full record

ReviewBest practice & research. Clinical anaesthesiology2021

Impact of COVID-19 infection on the cardiovascular system: An evidence-based analysis of risk factors and outcomes.

Alan D Kaye, Allyson L Spence, Mariah Mayerle, Nitish Sardana, Claire M Clay, Matthew R Eng, Markus M Luedi, Michelle A Carroll Turpin, Richard D Urman, Elyse M Cornett

Open access · greenAbstract readReview
In one paragraph

Review in Best practice & research. Clinical anaesthesiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 21 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 2 countries.

Alan D KayeDepartment of Anesthesiology and Pharmacology, Toxicology, and Neurosciences, LSU Health Shreveport, 1501 Kings Highway, Shreveport, LA, 71103, USA. Electronic address: akaye@lsuhsc.edu.
Allyson L SpenceDepartment of Pharmaceutical Sciences, Regis University School of Pharmacy, Denver, CO, 80221, USA. Electronic address: aspence002@regis.edu.
Mariah MayerleRegis University School of Pharmacy, Denver, CO, 80221, USA. Electronic address: mmayerle@regis.edu.
Nitish SardanaRutgers Robert Wood Johnson Medical School, 675 Hoes Ln W, Piscataway, NJ, 08854, USA. Electronic address: nitish.sardana@rutgers.edu.
Claire M ClayLSU Health Shreveport, 1501 Kings Highway, Shreveport, LA, 71103, USA. Electronic address: CClay2@lsuhsc.edu.
Matthew R EngDepartment of Anesthesiology, LSU Health Sciences Center, 1542 Tulane Avenue, New Orleans, LA, 70112, USA. Electronic address: meng@lsuhsc.edu.
Markus M LuediBern University Hospital Inselspital, University of Bern, Bern, Switzerland. Electronic address: Markus.luedi2@insel.ch.
Michelle A Carroll TurpinDepartment of Biomedical Sciences, College of Medicine, University of Houston, Health 2 Building, Room, 8037, USA. Electronic address: macarrol@central.uh.edu.
Richard D UrmanDepartment of Anesthesiology, Perioperative and Pain Medicine, Harvard Medical School, Brigham and Women's Hospital, 75 Francis St, Boston, MA, 02115, USA. Electronic address: rurman@bwh.harvard.edu.
Elyse M CornettDepartment of Anesthesiology, LSU Health Shreveport, 1501 Kings Highway, Shreveport, LA, 71103, USA. Electronic address: ecorne@lsuhsc.edu.
Louisiana State University Health Sciences Center Shreveport · USRegis University · USBrigham and Women's Hospital · USLouisiana State University Health Sciences Center New Orleans · USRutgers, The State University of New Jersey · USUniversity of Bern · CHUniversity of Houston · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as COVID-19, emerged in late 2019 in Wuhan, China. The World Health Organization declared the virus a pandemic on March 11, 2020. Disease progression from COVID-19 infection has shown significant symptom manifestations within organ systems beyond the respiratory system. The literature has shown increasing evidence of cardiovascular involvement during disease course and an associated increase in mortality among infected patients. Although the understanding of this novel virus is continually evolving, it is currently proposed that the mechanism by which the SARS-CoV-2 virus contributes to cardiovascular manifestations involves the ACE2 transmembrane protein. The protein ACE2 is highly expressed in blood vessel pericytes, and infection can result in microvascular dysfunction and subsequent acute coronary syndromes. Complications involving the cardiovascular system include myocardial infarction, arrhythmias, shock, and heart failure. In this evidence-based review, we discuss risk factors of cardiovascular involvement in COVID-19 infection, pathophysiology of COVID-19-related cardiovascular infection, and injury, COVID-19 effects on the cardiovascular system and corresponding treatments, and hematologic effects of COVID-19 and COVID-19 in heart transplant patients. Clinicians managing COVID-19 patients should appreciate the potential cardiovascular effects related to the disease process.

Indexed as

Cardiovascular DiseasesCardiovascular SystemCOVID-19Delivery of Health CareEvidence-Based PracticeHumansRisk FactorscardiovascularcoronavirusCOVIDhealthcarehearthematology

Identifiers

PMID34511231
PMCPMC7919539
OpenAlexW3133655839

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.